Sort
4,870 grants matching “glp 1”
Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic
$995,102Klaus Klumpp · Riboscience, Llc · R44 · FY2020 · DA
Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
$995,100Joshua Alfaro · Pharmain Corporation · R44 · FY2023 · CA
Development of VNLG-152R as novel therapeutic for triple negative breast cancer
$995,100Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2021 · CA
Development of VNLG-152R as novel therapeutic for triple negative breast cancer
$995,100Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2022 · CA
Advancing a novel potent Zika virus specific nucleoside analog to the clinic
$995,099Klaus Klumpp · Riboscience, Llc · R44 · FY2018 · AI
Advancing a novel potent Zika virus specific nucleoside analog to the clinic
$995,099Klaus Klumpp · Riboscience, Llc · R44 · FY2019 · AI
Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
$995,099Joshua Alfaro · Pharmain Corporation · R44 · FY2024 · CA
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine
$994,743Vira Bitko · Bluewillow Biologics, Inc. · R44 · FY2021 · AI
Phase IIB Transmural Systems Transcatheter Cavopulmonary Bypass Endograft
$994,736Nasser Rafiee · Transmural Systems, Llc · R44 · FY2022 · HL
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance
$994,179Neil A Fanger · Virtici, Llc · R44 · FY2021 · AI
SBIR Phase II: Minimally invasive device for restoration of ventricular diastolic recoil without blood contact
$994,019Christina M Bolch · Corinnova Inc · · FY2021 · TIP
Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation
$993,934Craig Gelfand · Advent Therapeutics, Inc. · R44 · FY2024 · HL
Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes
$993,807Dung "zung" Thai · Remd Biotherapeutics, Inc. · R44 · FY2020 · DK
Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes
$993,807Dung "zung" Thai · Remd Biotherapeutics, Inc. · R44 · FY2021 · DK
Advancing a novel potent Zika virus specific nucleoside analog to the clinic
$993,605Klaus Klumpp · Riboscience, Llc · R44 · FY2017 · AI
iOP-Connect System for Long-Term Continuous Monitoring of Glaucoma Therapy by means of an Implantable Autonomous Intraocular Pressure Sensor
$993,500Kevin Douglas Berg · Injectsense, Inc. · R44 · FY2022 · EY
Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices
$993,460Glenn Brunner · N8 Medical, Inc. · R44 · FY2023 · HL
Assessment of Multiple Dose Administration of Glucagon Receptor Blocker REMD477 in Type 1 Diabetes
$993,326Dung "zung" Thai · Remd Biotherapeutics, Inc. · R44 · FY2019 · DK
Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation
$993,128Craig Gelfand · Advent Therapeutics, Inc. · R44 · FY2025 · HL
Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy
$992,844Srinivas Sridhar · Theranano, Llc · R42 · FY2020 · CA
Teixobactin Development for Anthrax
$992,770Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2022 · AI
Enabling rapid and effective stroke thrombectomy procedures from a Transradial approach: Combining introducer sheath, guide catheter, and distal access catheter into a single device.
$992,721Jared Hutar · Piraeus Medical, Inc. · R44 · FY2023 · NS
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
$992,040Jay L Rothstein · Immunext, Inc. · R44 · FY2018 · AI
Device for Treatment of Cardiac No-Option Patients
$991,925Mengjun Wang · 3dt Holdings, Llc · R44 · FY2019 · HL
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
$991,804Jay L Rothstein · Immunext, Inc. · R44 · FY2017 · AI